Summit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016
September 05 2016 - 6:00AM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and C. difficile infection, will be announcing
its financial results for the second quarter and half year ended 31
July 2016 on Thursday, 8 September 2016.
Summit will host a conference call the same day
at 1:00pm BST / 8:00am EDT. Conference call information will be
included in the half year results press release and a replay of the
call will also be available through the Company's
website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease DMD and the infectious disease Clostridium
difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
Summit
Therapeutics |
|
|
Glyn Edwards / Richard Pye
(UK office) |
|
Tel: +44 (0)1235 443
951 |
Erik Ostrowski / Michelle
Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial
Advisers LLP |
|
|
(Nominated Adviser) |
|
|
Liam Murray / Tony
Rawlinson |
|
Tel: +44 (0)20 7148
7900 |
|
|
|
N+1
Singer |
|
|
(Broker) |
|
|
Aubrey Powell / Jen
Boorer |
|
Tel: +44 (0)20 7496
3000 |
|
|
|
MacDougall
Biomedical Communications |
|
|
(US media contact) |
|
Tel: +1 781 235 3060 |
Chris Erdman / Karen
Sharma |
|
cerdman@macbiocom.com
/ |
|
|
ksharma@macbiocom.com |
|
|
|
Consilium
Strategic Communications |
|
|
(Financial public
relations, UK) |
|
Tel: +44 (0)20 3709
5700 |
Mary-Jane Elliott / Sue
Stuart / |
|
summit@consilium-comms.com |
Jessica Hodgson / Lindsey
Neville |
|
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Oct 2023 to Oct 2024